Wire · opportunities
Health Check: 'Frustrated' Echo IQ ponders next move after shock FDA setback
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 9 September 2026 · Fusion42 review
Echo IQ's AI-driven heart failure detection tool Echosolv HF was rejected by the FDA due to being 'not substantially equivalent' under the 510(k) pathway, causing a sharp share price drop. The company is considering appeal, resubmission, or mediation, while maintaining significant cash reserves and continuing R&D.
This Wire brief sits within Fusion42's coverage of Medtech.
◆ ◆ The Wire takeaway
Echo IQ’s FDA rejection opens a narrow but critical window for you to challenge or resubmit under the 510(k) pathway; sharpening your regulatory approach in US medtech sales is now urgent to salvage market entry and valuation.
◆ Coverage
1 source · 9 Sep 2026
◆ Related on Wire
◆ Topics